Skip to main content

Day: April 27, 2025

Alkane and Mandalay Combine to Create Growing Gold and Antimony Producer

Written by Customer Service on . Posted in Mergers And Acquisitions.

Merger of Equals Increases Scale and Benefits All ShareholdersCreates powerful platform underpinned by a shared vision for growth. Three cash-generating mines in premier mining jurisdictions with strong organic growth. Projected gold equivalent production of ~160,0001 ounces in 2025, increasing to over ~180,0002 ounces in 2026. Robust proforma balance sheet: A$188 / C$167 million cash to fuel growth as at 31 March 20253. Increased scale and trading liquidity anticipated to drive valuation re-rate.PERTH, Australia and TORONTO, April 27, 2025 (GLOBE NEWSWIRE) — Alkane Resources Limited (ASX: ALK) (“Alkane”) and Mandalay Resources Corporation (“Mandalay”) (TSX: MND, OTCQB: MNDJF) are pleased to announce that they have agreed to combine in a “merger of equals” transaction and have executed a definitive arrangement agreement (the...

Continue reading

Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting

Written by Customer Service on . Posted in Public Companies.

NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of preclinical and translational pharmacokinetics (PK) data of CD38-SADA in a poster at the 2025 American Association of Cancer Research (AACR) Annual Meeting being held on April 25-30, 2025 in Chicago, IL. The poster titled “Preclinical and translational pharmacokinetic (PK) modeling of the self-assembling and disassembling (SADA) bispecific fusion protein CD38-SADA for first-in-human (FIH) pretargeted radioimmunotherapy (PRIT)” characterizes the plasma concentrations of CD38-SADA in animal models...

Continue reading

Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager

Written by Customer Service on . Posted in Public Companies.

Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profile Abpro and Celltrion have a strategic partnership for worldwide development and commercialization of ABP-102/CT-P72 HER2-positive cancers represent up to 30 percent of all cases of breast, gastric, pancreatic, colorectal and other forms of cancerWOBURN, Mass., April 27, 2025 (GLOBE NEWSWIRE) — Abpro Holdings, Inc. (Nasdaq:ABP) (“Abpro”), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases, and Celltrion, a leading biopharmaceutical company, today unveiled preclinical data for ABP-102/CT-P72 in an oral presentation at the American Association for Cancer Research® (AACR) Annual Meeting 2025, in the New Drugs on the Horizon session. ABP-102/CT-P72,...

Continue reading

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting

Written by Customer Service on . Posted in Public Companies.

Zoldonrasib, a RAS(ON) G12D-selective inhibitor, demonstrated acceptable tolerability and encouraging initial antitumor activity in patients with previously treated KRAS G12D mutant non-small cell lung cancer REDWOOD CITY, Calif., April 27, 2025 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced new clinical data for zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, as monotherapy in patients with KRAS G12D mutant non-small cell lung cancer (NSCLC). Results were highlighted in the official press program at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois, and will be featured in a late-breaking oral presentation on April 27, 2025, at 5:00 p.m. Central...

Continue reading

SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union

Written by Customer Service on . Posted in Public Companies.

STAMFORD, Conn., April 27, 2025 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the Company anticipates the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) will adopt an opinion on the marketing authorization application (MAA) for nirogacestat, an oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors in the second quarter of 2025. About SpringWorks Therapeutics SpringWorks is a commercial-stage biopharmaceutical company dedicated to improving the lives of patients with severe rare diseases and cancer. We developed and are commercializing OGSIVEO® (nirogacestat) as the first and only FDA-approved medicine for adults with desmoid tumors...

Continue reading

Risk Strategies acquires GMC Advisors, LLC

Written by Customer Service on . Posted in Mergers And Acquisitions.

Texas-based commercial lines agency adds to construction, manufacturing, and energy industry expertise BOSTON, April 27, 2025 (GLOBE NEWSWIRE) — Risk Strategies, a leading North American specialty insurance brokerage, risk management and consulting firm, announced today that it has acquired GMC Advisors, LLC., based in Houston. Terms of the deal were not disclosed. Headed by owner Greg Chubon, GMC Advisors is a specialist in commercial lines insurance products, with a focus on the construction and manufacturing industries, as well as companies in the energy sector. Founded in 2003, the firm has built a record of consistent growth propelled by specialty knowledge and a focus on helping middle-market companies in target industries. “It is great to add such deep industry expertise to our West Region as we continue to build out our...

Continue reading

UPDATE — Relmada Therapeutics To Present NDV-01 Data at AUA2025

Written by Customer Service on . Posted in Public Companies.

Data to be presented in Clinical Trials in Progress Session on Monday, April 28, 2025 CORAL GABLES, Fla., April 27, 2025 (GLOBE NEWSWIRE) — Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today announced the presentation of an abstract at the American Urology Association (AUA2025), taking place from April 26-29th in Las Vegas.Abstract OverviewAbstract Title:   Prospective Open Label Study to Evaluate the Safety and Efficacy of intravesical sustained release Gemcitabine Docetaxel combination (NDV-01) in High Risk NMIBCSession:   Clinical Trials in Progress: Bladder CancerLocation:   Hall C, The Square, Learning LabPresentation Date:   April 28, 2025Presentation Time   10:04 AM PT to 10:12 AM PT     About NDV-01NDV-01 is an investigational, innovative...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.